Novo Nordisk shares drop 15% after poor trial results for new obesity drug
Once-a-week injection achieved less weight loss than rival treatment
Once-a-week injection achieved less weight loss than rival treatment
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Participants in trial of amycretin injectable obesity drug lost an average of 24% of their body weight on highest dose
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Danish group loses share in diabetes drugs to rivals, with first-half sales growth easing to 8%
